Vital Therapies Company Profile (NASDAQ:VTL)

About Vital Therapies (NASDAQ:VTL)

Vital Therapies logoVital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient's liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company's ELAD System consists of approximately four disposable ELAD C3A cell cartridges.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VTL
  • CUSIP: N/A
  • Web:
  • Market Cap: $236.36 million
  • Outstanding Shares: 42,207,000
Average Prices:
  • 50 Day Moving Avg: $4.85
  • 200 Day Moving Avg: $3.55
  • 52 Week Range: $2.25 - $6.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.14
  • P/E Growth: -0.27
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.74 per share
  • Price / Book: 3.30
  • EBITDA: ($45,910,000.00)
  • Return on Equity: -66.10%
  • Return on Assets: -60.92%
  • Current Ratio: 10.71%
  • Quick Ratio: 10.71%
  • Average Volume: 163,471 shs.
  • Beta: 5.27
  • Short Ratio: 18.64

Frequently Asked Questions for Vital Therapies (NASDAQ:VTL)

What is Vital Therapies' stock symbol?

Vital Therapies trades on the NASDAQ under the ticker symbol "VTL."

How were Vital Therapies' earnings last quarter?

Vital Therapies, Inc. (NASDAQ:VTL) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.30) by $0.01. During the same period in the prior year, the business posted ($0.30) earnings per share. View Vital Therapies' Earnings History.

When will Vital Therapies make its next earnings announcement?

Vital Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Vital Therapies.

Where is Vital Therapies' stock going? Where will Vital Therapies' stock price be in 2017?

3 analysts have issued 1 year price targets for Vital Therapies' shares. Their forecasts range from $6.00 to $10.00. On average, they anticipate Vital Therapies' share price to reach $8.00 in the next year. View Analyst Ratings for Vital Therapies.

Who are some of Vital Therapies' key competitors?

Who are Vital Therapies' key executives?

Vital Therapies' management team includes the folowing people:

  • Faheem Hasnain, Chairman of the Board
  • Terence E. Winters Ph.D., Chief Executive Officer, Director
  • Michael V. Swanson M.B.A., Chief Financial Officer
  • Robert A. Ashley, Executive Vice President, Chief Technical Officer
  • Duane Nash M.D., Executive Vice President, Chief Business Officer
  • Aron P. Stern M.B.A., Chief Administrative Officer
  • Andrew Henry, Vice President - Clinical Operations
  • Andrea Loewen-Rodriguez, Vice President - Regulatory Affairs and Quality Assurance
  • Richard Murawski, Vice President - Manufacturing
  • John M. Dunn, General Counsel, Secretary

How do I buy Vital Therapies stock?

Shares of Vital Therapies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vital Therapies' stock price today?

One share of Vital Therapies stock can currently be purchased for approximately $5.75.

MarketBeat Community Rating for Vital Therapies (NASDAQ VTL)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  123 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Vital Therapies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vital Therapies (NASDAQ:VTL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $8.00 (39.13% upside)
Consensus Price Target History for Vital Therapies (NASDAQ:VTL)
Price Target History for Vital Therapies (NASDAQ:VTL)
Analysts' Ratings History for Vital Therapies (NASDAQ:VTL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$6.00HighView Rating Details
3/10/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
1/2/2017Canaccord GenuitySet Price TargetBuy$10.00N/AView Rating Details
3/14/2016Credit Suisse GroupReiterated RatingNeutral$9.00N/AView Rating Details
11/22/2015William BlairReiterated RatingHold$10.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Vital Therapies (NASDAQ:VTL)
Earnings by Quarter for Vital Therapies (NASDAQ:VTL)
Earnings History by Quarter for Vital Therapies (NASDAQ VTL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.32)N/AView Earnings Details
8/3/2017Q2 2017($0.30)($0.29)ViewListenView Earnings Details
5/9/2017Q1 2017($0.37)($0.39)ViewListenView Earnings Details
3/7/2017Q4 2016($0.36)($0.37)ViewListenView Earnings Details
11/3/2016Q316($0.32)($0.32)ViewN/AView Earnings Details
8/2/2016Q216($0.33)($0.30)ViewN/AView Earnings Details
5/9/2016Q1($0.28)($0.31)ViewN/AView Earnings Details
3/8/2016Q415($0.42)($0.34)ViewN/AView Earnings Details
11/5/2015Q315($0.58)($0.51)ViewListenView Earnings Details
7/30/2015Q215($0.62)($0.63)ViewListenView Earnings Details
5/12/2015Q1($0.62)($0.62)ViewListenView Earnings Details
3/19/2015Q414($0.59)($0.59)ViewListenView Earnings Details
11/13/2014Q314($0.63)($0.59)ViewN/AView Earnings Details
8/6/2014Q214($0.04)($0.91)ViewN/AView Earnings Details
6/3/2014($0.54)($24.49)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vital Therapies (NASDAQ:VTL)
Current Year EPS Consensus Estimate: $-1.29 EPS
Next Year EPS Consensus Estimate: $-1.39 EPS


Dividend History for Vital Therapies (NASDAQ:VTL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Vital Therapies (NASDAQ:VTL)
Insider Ownership Percentage: 32.60%
Institutional Ownership Percentage: 25.58%
Insider Trades by Quarter for Vital Therapies (NASDAQ:VTL)
Institutional Ownership by Quarter for Vital Therapies (NASDAQ:VTL)
Insider Trades by Quarter for Vital Therapies (NASDAQ:VTL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/14/2017Muneer A SatterDirectorBuy130,000$4.01$521,300.00View SEC Filing  
9/13/2017Jean Jacques BienaimeDirectorBuy10,000$4.00$40,000.00View SEC Filing  
9/8/2017Muneer A SatterDirectorBuy50,000$3.53$176,500.00View SEC Filing  
6/14/2017John Michael DunnGeneral CounselBuy2,500$3.09$7,725.00View SEC Filing  
6/14/2017Muneer A SatterDirectorBuy20,000$3.07$61,400.00View SEC Filing  
6/14/2017Terence E WintersChairmanBuy10,000$3.10$31,000.00View SEC Filing  
6/13/2017Muneer A SatterDirectorBuy10,000$3.03$30,300.00View SEC Filing  
6/12/2017Muneer A SatterDirectorBuy30,000$3.11$93,300.00View SEC Filing  
6/9/2017Robert A AshleyInsiderBuy2,000$3.18$6,360.00View SEC Filing  
6/8/2017Duane NashPresidentBuy3,900$3.12$12,168.00View SEC Filing  
6/7/2017Muneer A SatterDirectorBuy20,000$3.20$64,000.00View SEC Filing  
6/6/2017Muneer A SatterDirectorBuy10,000$3.19$31,900.00View SEC Filing  
3/27/2017Muneer A SatterDirectorBuy3,750,000$4.00$15,000,000.00View SEC Filing  
8/12/2016Faheem HasnainDirectorBuy118,243$5.92$699,998.56View SEC Filing  
10/28/2015Muneer A SatterDirectorBuy400,000$5.50$2,200,000.00View SEC Filing  
10/26/2015Cheryl CohenDirectorBuy3,500$7.17$25,095.00View SEC Filing  
10/26/2015John Michael DunnGeneral CounselBuy9,385$6.81$63,911.85View SEC Filing  
9/10/2015Jean Jacques BienaimeDirectorBuy14,000$3.08$43,120.00View SEC Filing  
10/10/2014Terence E WintersCEOBuy1,360$14.86$20,209.60View SEC Filing  
10/8/2014Duane NashInsiderBuy100$17.50$1,750.00View SEC Filing  
10/8/2014Lowell SearsDirectorBuy1,429$17.50$25,007.50View SEC Filing  
6/3/2014Muneer A SatterDirectorBuy14,500$13.16$190,820.00View SEC Filing  
4/23/2014Muneer A SatterDirectorBuy360,966$12.00$4,331,592.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Vital Therapies (NASDAQ:VTL)
Latest Headlines for Vital Therapies (NASDAQ:VTL)
DateHeadline logo Analysts Anticipate Vital Therapies, Inc. (VTL) Will Post Earnings of -$0.30 Per Share - October 17 at 12:52 PM logoBidaskClub Upgrades Vital Therapies, Inc. (VTL) to Strong-Buy - October 5 at 11:20 PM logoVital Therapies, Inc. (VTL) Receives Consensus Rating of "Hold" from Brokerages - October 5 at 10:20 PM logoVital Therapies, Inc. (VTL) Stock Rating Lowered by Zacks Investment Research - October 5 at 6:58 PM logoReviewing Vital Therapies (VTL) and The Competition - October 5 at 12:16 AM logoAll You Need To Know About Vital Therapies Inc’s (VTL) Risks - October 3 at 2:44 PM logoIs It Too Late To Buy Vital Therapies Inc (VTL)? - September 16 at 10:17 AM logoInsider Buying: Vital Therapies, Inc. (VTL) Director Buys 10,000 Shares of Stock - September 14 at 11:56 PM logoVital Therapies, Inc. (VTL) Director Muneer A. Satter Purchases 130,000 Shares - September 14 at 10:52 PM logoVital Therapies, Inc. (VTL) Director Buys $176,500.00 in Stock - September 12 at 7:54 PM logoVital Therapies Announces Recent and Upcoming Scientific Presentations and Participation in Upcoming Investor Conference - September 11 at 8:25 AM logoVital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors - September 6 at 8:23 AM logoEdited Transcript of VTL earnings conference call or presentation 3-Aug-17 8:30pm GMT - August 5 at 8:24 AM logoVital Therapies Announces Second Quarter 2017 Financial Results - August 4 at 9:53 AM logoVital Therapies, Inc. (NASDAQ:VTL) Issues Quarterly Earnings Results - August 4 at 12:50 AM logoVital Therapies, Inc. (VTL) Set to Announce Earnings on Monday - July 24 at 8:43 AM logoVital Therapies, Inc. (VTL) Expected to Post Earnings of -$0.30 Per Share - July 13 at 12:22 AM logoVital Therapies reports 1Q loss - May 9 at 7:28 PM logoVITAL THERAPIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statement - March 23 at 8:57 PM logoVITAL THERAPIES INC Files SEC form 8-K, Other Events - March 21 at 8:21 PM logoVital Therapies Announces Fourth Quarter and Full Year 2016 Financial Results - March 8 at 12:24 AM logo4:02 pm Vital Therapies misses by $0.01 - March 8 at 12:24 AM logoQ4 2016 Vital Therapies Inc Earnings Release - After Market Close - March 7 at 8:19 AM logoQ3 2016 Vital Therapies Inc Earnings Release - After Market Close - November 3 at 12:39 PM logoVital Therapies (VTL) Offers Corporate Update; Says 14 Subjects Enrolled in VTL-308 - September 15 at 8:09 PM logoVITAL THERAPIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement - August 29 at 8:05 PM logoVITAL THERAPIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - August 15 at 10:14 AM logoVital Therapies Announces Second Quarter Financial Results - August 2 at 8:37 PM logoQ2 2016 Vital Therapies Inc Earnings Release - After Market Close - August 2 at 7:22 AM logoVITAL THERAPIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of - May 27 at 4:33 PM logoVITAL THERAPIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib - May 9 at 5:13 PM logoQ1 2016 Vital Therapies Inc Earnings Release - After Market Close - May 9 at 7:07 AM



Vital Therapies (VTL) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.